Endeavor Biomedicines, Inc. announced it raised $89.1 Million in an initial filing from an offering of $101 Million

Company

Location

About

Endeavor BioMedicines is a clinical stage company targeting the drivers of fibrosis and oncology. We combine best-in-class therapeutics with an evolving understanding of terminal diseases to develop medicines with the potential to reverse severe health conditions. Our lead program, ENV-101, is a Hedgehog signaling inhibitor with demonstrated clinical activity that we are investigating in IPF. At Endeavor, we are an innovative and focused team that has come together to live up to our name and bold mission: to help patients feel better and live longer.